Oxford-MUHAS Research Breakthrough: Liquid Biopsy Reduces Burkitt Lymphoma Diagnosis Time by 40 Days in Sub-Saharan Africa

Oxford and MUHAS researchers use liquid biopsy to diagnose Burkitt lymphoma 40 days faster in Africa, raising survival hopes for thousands of children.

By: AXL Media

Published: Mar 23, 2026, 7:11 AM EDT

Source: Information for this report was sourced from [University of Oxford]

Revolutionizing Pediatric Oncology in Resource-Limited Settings

Getty Images

Burkitt lymphoma is an exceptionally aggressive but highly curable cancer, boasting survival rates over 90% when treated promptly. While life-saving medication is often provided free of charge in many sub-Saharan African countries, the primary barrier to survival remains the diagnostic process. Traditional tissue biopsies require specialized pathology expertise and sophisticated laboratory equipment that are frequently unavailable in rural or under-resourced hospitals. Consequently, many children go undiagnosed or receive a diagnosis only after the disease has reached a fatal stage, causing regional survival rates to plummet below 50%.

The Mechanics of Non-Invasive Genetic Detection

The liquid biopsy approach developed by the international team offers a practical alternative to invasive surgery. By analyzing a simple blood sample, the test can detect tiny fragments of DNA released by cancer cells into the bloodstream. These fragments contain specific genetic mutations characteristic of Burkitt lymphoma, allowing scientists to distinguish the tumor from healthy cells or other types of cancer. Professor Anna Schuh of the University of Oxford noted that this precise, minimally invasive method has the potential to transform the diagnostic landscape for children and young adults across the region.

Drastic Improvements in Diagnostic Speed and Accuracy